Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC

Introduction: Radiological response assessment to immune checkpoint inhibitor is challenging due to atypical pattern of response and commonly used RECIST 1.1 criteria do not take into account the kinetics of tumor behavior. Our study aimed at evaluating the tumor growth rate (TGR) in addition to REC...

Full description

Bibliographic Details
Main Authors: Filippo G. Dall’Olio, Claudia Parisi, Laura Marcolin, Stefano Brocchi, Caroline Caramella, Nicole Conci, Giulia Carpani, Francesco Gelsomino, Stefano Ardizzoni, Paola Valeria Marchese, Alexandro Paccapelo, Giada Grilli, Rita Golfieri, Benjamin Besse, Andrea Ardizzoni
Format: Article
Language:English
Published: SAGE Publishing 2022-02-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211058391

Internet

https://doi.org/10.1177/17588359211058391

Similar Items